Bovine respiratory disease treatment market

Bovine respiratory disease (BRD) is the most common disease, affecting the lower respiratory tract of cattle, causing bronchopneumonia and can lead to death. It is a multi-factorial syndrome that is mainly caused when a viral infection combines with a bacterial agent, and is further amplified by stress. BRD has numerous causes such as bacterial agents, including pasteurella multocida, haemophilus somnus, mannheimia haemolytica, and viral agents such as infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea (BVD), and parainfluenza type-3 virus (PI-3).

Increasing cattle production due to rising demand for animal meat is expected to drive growth of bovine respiratory disease treatment market

According to a study published in the Turkish Journal of Veterinary and Animal Sciences in 2016, bovine respiratory disease (BRD) is the most common disease found in cattle, causing around 75% of morbidity and accounting for over 50% of cattle deaths. The increasing prevalence of BRD among cattle is expected to drive growth of the bovine respiratory disease treatment market in near future.

According a study published by the U.S. Department of Agriculture (USDA) in 2016, cattle production is one of the most important industries in the U.S., valued at US$ 78.2 billion in 2015. Growing population in turn, is increasing demand for cattle meat and milk products, which increases rate of cattle rearing. Increasing cattle rearing inadvertently, increases the prevalence of BRD in cattle. This is expected to create a lucrative environment for growth of bovine respiratory disease treatment market in the near future.

The global bovine respiratory disease treatment market is segmented on the basis of disease, treatment type, and distribution channel. 

On the basis of disease, the global bovine respiratory disease treatment market is segmented into:

• Diphtheria
• Upper Respiratory Tract Infections
• Pneumonia (lower respiratory tract infection)

On the basis of drug type, the global bovine respiratory disease treatment market is segmented into:

• Antibiotics
• NSAIDs
• Vaccines
• Immunomodulators
• Others

On the basis of distribution channel, the global bovine respiratory disease treatment market is segmented into:

• Veterinary Hospitals
• Retail Pharmacies
• Online Pharmacies

North America is expected to hold a dominant position in the bovine respiratory disease treatment market, owing to increasing prevalence of bovine respiratory disease

North America is expected to hold a dominant position in the bovine respiratory disease treatment market due to increasing prevalence of bovine respiratory disease in the region. According to Bovine Respiratory Disease Symposium, 2014, Bovine respiratory disease (BRD) is a worldwide health concern and is very common among cattle in North America. In feedlots, BRD accounts for 70-80% of all feedlot morbidity and 40-50% of all mortality, in the U.S. Asia Pacific is expected to show significant growth in bovine respiratory disease market due to increasing rearing of cattle in China. For instance, according to an article published by the U.S. Department of Agriculture in 2017, China is the world’s second-largest beef meat exporter.

Increasing development of innovative treatment measures for bovine respiratory disease to boost market growth

Key players in bovine respiratory disease treatment market include Zoetis Inc., Bayer AG, Merck & Co., Inc., Virbac Group, Boehringer Ingelheim GmbH, Elanco, Vetoquinol, and Bimeda Animal Health. In 2015, Bayer launched Immunostimulant Zelnate, which effectively reduces bovine respiratory disease (BRD) associated mortality and lung lesions in cattle. Zelnate is the first cytosine-phosphate-guanine (CpG) motif-based immunostimulant authorized by the U.S. Department of Agriculture.